CA3243247A1 - COMBINATIONS OF CHEMOTHERAPY AGENTS AND SMALL TISSUE FIXING MOLECULES, COMPOSITIONS AND ASSOCIATED METHODS - Google Patents

COMBINATIONS OF CHEMOTHERAPY AGENTS AND SMALL TISSUE FIXING MOLECULES, COMPOSITIONS AND ASSOCIATED METHODS

Info

Publication number
CA3243247A1
CA3243247A1 CA3243247A CA3243247A CA3243247A1 CA 3243247 A1 CA3243247 A1 CA 3243247A1 CA 3243247 A CA3243247 A CA 3243247A CA 3243247 A CA3243247 A CA 3243247A CA 3243247 A1 CA3243247 A1 CA 3243247A1
Authority
CA
Canada
Prior art keywords
compound
mmol
mixture
pct
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243247A
Other languages
English (en)
French (fr)
Inventor
Ninghui Yu
Rongliang Lou
Original Assignee
Canwell Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canwell Biotech Ltd filed Critical Canwell Biotech Ltd
Publication of CA3243247A1 publication Critical patent/CA3243247A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/40—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3243247A 2022-02-08 2023-02-03 COMBINATIONS OF CHEMOTHERAPY AGENTS AND SMALL TISSUE FIXING MOLECULES, COMPOSITIONS AND ASSOCIATED METHODS Pending CA3243247A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/075427 2022-02-08
PCT/CN2022/075427 WO2023150899A1 (en) 2022-02-08 2022-02-08 Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
PCT/CN2023/074329 WO2023151513A1 (en) 2022-02-08 2023-02-03 Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof

Publications (1)

Publication Number Publication Date
CA3243247A1 true CA3243247A1 (en) 2023-08-17

Family

ID=87563330

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243247A Pending CA3243247A1 (en) 2022-02-08 2023-02-03 COMBINATIONS OF CHEMOTHERAPY AGENTS AND SMALL TISSUE FIXING MOLECULES, COMPOSITIONS AND ASSOCIATED METHODS

Country Status (8)

Country Link
US (1) US20250082657A1 (enExample)
EP (1) EP4476226A1 (enExample)
JP (1) JP2025507308A (enExample)
CN (1) CN118946569A (enExample)
AU (1) AU2023217770A1 (enExample)
CA (1) CA3243247A1 (enExample)
IL (1) IL314835A (enExample)
WO (2) WO2023150899A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118515573B (zh) * 2024-07-19 2024-09-27 浙江省产品质量安全科学研究院 一种稳定同位素标记的氘代奥拉氟化合物的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350756B1 (en) * 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
CN1982313B (zh) * 2005-12-13 2010-12-01 深圳市天和医药科技开发有限公司 10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
US20160095939A1 (en) * 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9150585B2 (en) * 2012-11-13 2015-10-06 Fl Therapeutics Llc Analogs of camptothecin
CN103848840A (zh) * 2012-12-03 2014-06-11 中国人民解放军军事医学科学院毒物药物研究所 喜树碱衍生物及其医药用途
CN105315294B (zh) * 2014-06-26 2018-05-01 王杭祥 7-乙基-10-羟基喜树碱药物前体及其制备方法和应用
CN104447777B (zh) * 2014-11-26 2016-09-14 浙江大学 一种辣椒碱-喜树碱类抗癌药物偶联物及其制备方法和应用
CN106377528B (zh) * 2016-08-19 2019-05-31 湖北医药学院 一种羟基喜树碱戊二酸单酯的药物组合物
CN106588946B (zh) * 2017-01-25 2019-01-22 郑州大学 10-羟基喜树碱衍生物、合成方法及其应用
KR101990214B1 (ko) * 2017-12-12 2019-06-17 고려대학교 산학협력단 표적 특이적 항암 약물전구체
CN109675050A (zh) * 2018-12-27 2019-04-26 浙江工业大学 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用
CN110372766A (zh) * 2019-06-21 2019-10-25 广州中医药大学(广州中医药研究院) 喜树碱糖类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
WO2023151513A1 (en) 2023-08-17
US20250082657A1 (en) 2025-03-13
AU2023217770A1 (en) 2024-08-22
JP2025507308A (ja) 2025-03-18
WO2023150899A1 (en) 2023-08-17
CN118946569A (zh) 2024-11-12
IL314835A (en) 2024-10-01
EP4476226A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
JP7394074B2 (ja) 治療用化合物
CN102821602B (zh) 脂肪酸富马酸酯衍生物及其用途
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
KR20190038485A (ko) Fgfr4 저해제인 헤테로 고리 화합물
CN116848104B (zh) 一种前药化合物及其制备方法和用途
AU2019296085A1 (en) Heterocyclic compound as TRK inhibitor
CN113735881A (zh) 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
KR20210141461A (ko) 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도
JP2023109924A (ja) ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
WO2019218904A1 (zh) 非天然氨基酸类衍生物、其制备方法及用途
JP7201800B2 (ja) Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
CA3243247A1 (en) COMBINATIONS OF CHEMOTHERAPY AGENTS AND SMALL TISSUE FIXING MOLECULES, COMPOSITIONS AND ASSOCIATED METHODS
IL314070A (en) Macrocyclic compounds and use as kinase inhibitors
CA3179325A1 (en) Kinase inhibitors and uses thereof
CN114181161A (zh) (2-((取代氧基)苯基)氨基)嘧啶-4-基)氨基苯甲酰衍生物及其制备方法与应用
WO2023215803A2 (en) Cytochrome bd oxidase inhibitors and uses thereof
CN117510504A (zh) 蛋白激酶降解剂、药物及应用
CA3145680A1 (en) Pyridine derivative as fgfr and vegfr dual inhibitors
HK40118706A (zh) 化疗药物和组织结合小分子的缀合物、其组合物和方法
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
CA3213624A1 (en) Metap-2 inhibitors, pharmaceutical compositions and therapeutic methods thereof
CN116903626A (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2023119098A1 (en) Protein kinase c theta inhibitors
WO2025010326A2 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240723

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240725

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240725

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240725

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251231

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251231